LONDON, July 19,
2022 /PRNewswire/ -- LumiraDx Limited (Nasdaq: LMDX),
a next-generation point of care (POC) diagnostics company, today
announced that it has commenced an underwritten public offering of
40,000,000 common shares. All of the shares in the proposed
offering are to be sold by LumiraDx. In addition, LumiraDx intends
to grant the underwriters a 30-day option to purchase up to an
additional 6,000,000 common shares at the public offering price.
The proposed offering is subject to market and other conditions,
and there can be no assurance as to whether or when the offering
may be completed or the actual size or terms of the offering.
LumiraDx expects to use the net proceeds from this offering,
together with its existing cash and cash equivalents, principally
for general corporate purposes, including working capital in
respect to R&D, business development, and sales and marketing
activities as well as ordinary course capital expenditures.
Goldman Sachs & Co. LLC, Evercore ISI, SVB Securities and
Raymond James are acting as joint
book-running managers for the proposed offering.
The proposed offering of these securities will be made only by
means of a prospectus. When available, copies of the preliminary
prospectus relating to these securities may be obtained for free
from any of the book-running managers for the proposed offering:
Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200
West Street, New York, NY 10282,
by telephone at (866) 471-2526 or by email at
prospectus-ny@ny.email.gs.com; Evercore Group L.L.C., Attention:
Equity Capital Markets, 55 East 52nd Street, 36th Floor,
New York, NY 10055, by telephone
at (888) 474-0200, or by email at ecm.prospectus@evercore.com; SVB
Securities LLC, Attention: Syndicate Department, 53 State Street,
40th Floor, Boston, MA 02109, by
telephone at (800) 808-7525, ext. 6105, or by email at
syndicate@svbsecurities.com; or Raymond
James & Associates, Inc., Attention: Syndicate
Department, 880 Carillon Parkway, St.
Petersburg, FL 33716, by telephone at (800) 248-8863, or by
email at prospectus@raymondjames.com.
A registration statement, including a prospectus, which is
preliminary and subject to completion, relating to these securities
has been filed with the U.S. Securities and Exchange Commission
("SEC"), but has not yet become effective. These securities may not
be sold, nor may offers to buy be accepted, prior to the time that
the registration statement becomes effective. This press release
does not constitute an offer to sell, or a solicitation of an offer
to buy securities, any securities, nor shall there be any sale of
securities in any state or jurisdiction in which such an offer,
solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or
jurisdiction.
About LumiraDx
LumiraDx (Nasdaq: LMDX) is a next-generation point of care
diagnostics company that is transforming community-based
healthcare. Founded in 2014, LumiraDx manufactures and
commercializes an innovative diagnostic Platform that supports a
broad menu of tests with lab comparable performance at the
point of care. LumiraDx's diagnostic testing solutions are being
deployed by governments and leading healthcare institutions across
laboratories, urgent care, physician offices, pharmacies, schools,
and workplaces to screen, diagnose, and monitor wellness as well as
disease. LumiraDx has, on the market and in development, 30+ tests
covering infectious diseases, cardiovascular diseases, diabetes,
and coagulation disorders, all on the LumiraDx Platform. In
addition, LumiraDx has a comprehensive portfolio of fast, accurate,
and cost-efficient COVID-19 testing solutions from the lab to point
of need. LumiraDx is based in the UK with more than 1600 employees
worldwide.
Forward-Looking Statements
This press release contains forward-looking statements as
defined in Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended,
that involve significant risks and uncertainties. Such statements
relate to a variety of matters, including, without limitation, the
company's expectations regarding the sale of its common shares in
the proposed offering, use of the proceeds from the proposed
offering, the grant of the option to purchase additional shares,
and other statements that are not purely statements of historical
fact. These forward-looking statements include information about
the terms of the offering, our ability to consummate the offering
and our intended use of proceeds. Words such as "expects,"
"intends," "plans," "believes," "anticipates," "estimates," and
variations of such words and similar expressions are intended to
identify such forward looking statements.
Although we believe that the forward-looking statements
contained in this press release are based on reasonable
assumptions, you should be aware that many factors could cause
actual results to differ materially from those in such
forward-looking statements, including but not limited to: general
economic, political and business conditions; the effect of COVID-19
on LumiraDx's business and financial results; obtaining or
maintaining regulatory approval, authorization or clearance for our
tests; and those factors discussed under the header "Risk Factors"
in the preliminary prospectus relating to the securities, when
available, in our Annual Report on Form 20-F for the year ended
December 31, 2021, which was filed
with the SEC on April 13, 2022 and in
other filings that we make with the SEC.
Readers are cautioned not to place undue reliance on these
forward-looking statements, which speak only as of the date of this
press release. We undertake no obligation to publicly update or
revise any forward-looking statements contained herein, to reflect
any change in our expectations with respect to such statements or
any change in events, conditions or circumstances upon which any
statement is based.
Contact:
Colleen
McMillen
Colleen.McMillen@lumiradx.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/lumiradx-announces-proposed-public-offering-of-common-shares-301589167.html
SOURCE LumiraDx